Related Experiment Videos
One-sided sequential stopping boundaries for clinical trials: a decision-theoretic approach
Biometrics
|March 1, 1988
Summary
This study introduces a decision-theoretic approach for clinical trial stopping rules. It optimizes sequential decisions to maximize pharmaceutical company profits while ensuring drug safety and efficacy.
Area of Science:
- Decision theory
- Clinical trial methodology
- Pharmaceutical development
Background:
- Clinical trials require careful management of efficacy and safety data.
- Stopping rules are crucial for ethical and economic reasons in drug development.
- Balancing early termination for futility with the need for safety demonstration is complex.
Purpose of the Study:
- To develop a decision-theoretic framework for one-sided stopping rules in clinical trials.
- To guide pharmaceutical companies in maximizing expected profits during drug development.
- To integrate efficacy and safety considerations into sequential trial decision-making.
Main Methods:
- Application of decision theory to sequential clinical trial analysis.
- Modeling of stopping rules based on efficacy and safety data.
- Optimization of decision policies for pharmaceutical companies.
Main Results:
- Demonstration of how to sequentially decide trial continuation or termination.
- Quantification of the trade-offs between early stopping for negative efficacy and continued development for safety.
- A framework for maximizing expected profits in drug development.
Conclusions:
- Optimized stopping rules enhance the efficiency of drug development.
- Decision theory provides a robust framework for managing clinical trial decisions.
- Integrating profit maximization with safety and efficacy is achievable through sequential decision analysis.